Botulinum toxin in otolaryngology: A review of its actions and opportunities for use

Ear, Nose and Throat Journal

Volumn 79, Issue 10, 2000, Pages 788-801

  Neuenschwander, M C ^a   Pribitkin, E A ^a   Sataloff, R T ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOPHENAZONE; BOTULINUM TOXIN A; GUANIDINE;

ARTICLE; BLEPHAROSPASM; CHOLINERGIC RECEPTOR BLOCKING; DENERVATION; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DYSPHONIA; DYSTONIA; FACIAL NERVE PARALYSIS; HEMIFACIAL SPASM; HUMAN; LETHAL DOSE; MUSCLE SPASM; NONHUMAN; SIDE EFFECT; TORTICOLLIS;

EID: 0033766662     PISSN: 01455613     EISSN: None     Source Type: Journal    
DOI: 10.1177/014556130007901010     Document Type: Article

References (52)

1. Botulinum toxin: The story of its development for the treatment of human disease
2. Consensus Development Panel on Clinical Use of Botulinum Toxin. Botulinum toxin
3. Botulinum toxin as a therapeutic agent
4. Clinically relevant aspects of the mechanism of action of botulinum neurotoxin
5. Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: A double-blind, controlled study
6. Nerve growth in botulinum toxin poisoned muscles
7. Changes in the electron microscopic structure of slow and fast skeletal muscle fibres of the mouse after the local injection of botulinum toxin
8. The effects of botulinum toxin on the pattern of innervation of skeletal muscle in the mouse
9. Anatomic considerations in botulinum toxin type A therapy for spasmodic dysphonia
10. Effect of neuromuscular activity on the response to botulinum toxin injections in spasmodic dysphonia
11. Absence of antibody production in patients treated with botulinum A toxin
12. Crystalline preparation of botulinum toxin type A (Botox): Degradation in potency with storage
13. Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use
14. Laryngeal dystonia: A series with botulinum toxin therapy
15. Treatment of spasmodic dysphonia (laryngeal dystonia) with local injections of botulinum toxin
16. Effects of botulinum toxin therapy in patients with adductor spasmodic dysphonia: Acoustic, aerodynamic, and videoendoscopic findings
17. Functional assessment of patients with spasmodic dysphonia
18. Indirect laryngoscopic approach for injection of botulinum toxin in spasmodic dysphonia
19. Botulinum toxin treatment of spasmodic dysphonia: Techniques, indications, efficacy
20. Long-term effects of botulinum toxin injections in spasmodic dysphonia
21. Spasmodic dysphonia
22. Comparison of botulinum toxin injection procedures in adductor spasmodic dysphonia
23. Technique for injection of botulinum toxin through the flexible nasolaryngoscope
24. Quantitative mapping of the effect of botulinum toxin injections in the thyroarytenoid muscle
25. A comparison of the efficacy of unilateral versus bilateral botulinum toxin injections in the treatment of adductor spasmodic dysphonia
26. Prospective study of patients' subjective responses to botulinum toxin injection for spasmodic dysphonia
27. Unilateral versus bilateral botulinum toxin injections in spasmodic dysphonia: Acoustic and perceptual results
28. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia
29. Laryngeal botulinum toxin injections for disabling stuttering in adults
30. Successful treatment of selected cases of abductor spasmodic dysphonia using botulinum toxin injection
31. Abductor laryngeal dystonia: A series treated with botulinum toxin
32. Treatment of adductor laryngeal breathing dystonia with botulinum toxin type A
33. Treatment selections of 239 patients with blepharospasm and Meige syndrome over 11 years
34. Essential blepharospasm and related dystonias
35. Treatment of blepharospasm and hemifacial spasm with botulinum A toxin: A Canadian multicentre study
36. Blepharospasm and hemifacial spasm. Randomized trial to determine the most appropriate location for botulinum toxin injections
37. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm
38. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm
39. Management of facial spasm with Clostridium botulinum toxin, type A
40. Botulinum toxin injection for the treatment of oromandibular dystonia
41. Botulinum A toxin for the treatment of spasmodic torticollis: Dysphagia and regional toxin spread
42. Botulinum-A toxin in the treatment of craniocervical muscle spasms: Short- and long-term, local and systemic effects
43. Botulinum A toxin for treatment of aberrant facial nerve regeneration
44. Bell's palsy: Management of sequelae using EMG rehabilitation, botulinum toxin, and surgery
45. Botulinum A exotoxin use in clinical dermatology
46. Botulinum toxin A for hyperkinetic facial lines: Results of a double-blind, placebo-controlled study
47. Patient selection in the treatment of glabellar wrinkles with botulinum toxin type A injection
48. Botulinum toxin for the treatment of hyperfunctional lines of the face
49. Botulinum A exotoxin for glabellar folds: A double-blind, placebo-controlled study with an electromyographic injection technique
50. Voice failure after tracheoesophageal puncture: Management with botulinum toxin
51. Use of botulinum toxin for diagnosis and management of cricopharyngeal achalasia
52. Controlled trial of botulinum toxin injection versus placebo and pneumatic dilation in achalasia